Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	5.21	2.23	2.52	3.53	3.93
Revenue Growth (YoY)	133.58%	-11.61%	-28.54%	-10.17%	122.86%
Cost of Revenue	7.22	7.59	19.84	4.69	4.39
Gross Profit	-2.01	-5.36	-17.31	-1.16	-0.46
Selling, General & Admin	4.72	5.36	6.91	18.71	1.15
Operating Expenses	4.72	5.36	6.91	18.71	1.15
Operating Income	-6.73	-10.72	-24.22	-19.87	-1.61
Interest Expense	-1.29	-0.35	-1.25	-3.22	-1
Other Non Operating Income (Expenses)	0.03	0.3	-0.53	-2.91	2.45
EBT Excluding Unusual Items	-7.99	-10.77	-26	-26	-0.16
Other Unusual Items	-	0.15	1.79	-3.15	-
Pretax Income	-7.99	-10.63	-24.21	-29.15	-0.16
Earnings From Continuing Operations	-7.99	-10.63	-24.21	-29.15	-0.16
Minority Interest in Earnings	0	0.01	0.04	0.06	0.22
Net Income	-7.99	-10.61	-24.17	-29.08	0.06
Preferred Dividends & Other Adjustments	0	0.01	0.91	0.8	-
Net Income to Common	-7.99	-10.63	-25.09	-29.89	0.06
Shares Outstanding (Basic)	1	0	0	-	-
Shares Outstanding (Diluted)	1	0	0	-	-
Shares Change (YoY)	362.24%	1158.33%	-	-	-
EPS (Basic)	-11.45	-70.40	-2091.33	-	-
EPS (Diluted)	-11.45	-70.40	-2091.33	-	-
Gross Margin	-38.57%	-240.17%	-	-32.82%	-11.66%
Operating Margin	-129.18%	-480.52%	-959.91%	-562.71%	-41.04%
Profit Margin	-153.31%	-476.39%	-994.12%	-846.37%	1.44%
EBITDA	-	-	-24.22	-19.87	-1.61
EBITDA Margin	-	-	-	-	-41.03%
D&A For EBITDA	-	-	0	0	0
EBIT	-6.73	-10.72	-24.22	-19.87	-1.61
EBIT Margin	-129.18%	-	-	-	-41.04%

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q